A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH with liver fibrosis. METHODS: We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned in a 1:1:1 ratio to receive once-daily resmetirom at a dose of 80 mg or 100 mg or placebo. The two primary end points at week 52 were NASH resolution (including a reduction in the nonalcoholic fatty liver disease [NAFLD] activity score by ≥2 points; scores range from 0 to 8, with higher scores indicating more severe disease) with no worsening of fibrosis, and an improvement (reduction) in fibrosis by at least one stage with no worsening of the NAFLD activity score. RESULTS: Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group). NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P<0.001 for both comparisons with placebo). Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo). The change in low-density lipoprotein cholesterol levels from baseline to week 24 was -13.6% in the 80-mg resmetirom group and -16.3% in the 100-mg resmetirom group, as compared with 0.1% in the placebo group (P<0.001 for both comparisons with placebo). Diarrhea and nausea were more frequent with resmetirom than with placebo. The incidence of serious adverse events was similar across trial groups: 10.9% in the 80-mg resmetirom group, 12.7% in the 100-mg resmetirom group, and 11.5% in the placebo group. CONCLUSIONS: Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Therefore, incretinbased medications for the treatment of MASLD could be made available, supplementing resmetirom as the only approved medication in the USA and Europe.87”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [87]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Resmetirom is the first compound approved for the treatment of MASH in conjunction with diet and exercise, showing the importance of combining lifestyle changes to pharmacological treatment.91”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was not until March 2024 that the U.S. Food and Drug Administration (FDA) approved the first drug, Rezdiffra, for non-alcoholic steatohepatitis (NASH) with liver fibrosis.”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resmetirom, a THRβ agonist, showed antisteatogenic potential in a 36-week phase 2 RCT in people with biopsy-confirmed MASH and fibrosis, accompanied by a rise in circulating adiponectin and improved plasma lipid profile [210,211].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [211]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About 14% of participants in the MAESTRO-NASH trial were on GLP1RA treatment, with stable dosage in the 6 months and stable body weight in the 3 months preceding screening liver biopsy.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [350]
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationAlberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationEstes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Self-citationMechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citation
Research works printed but not linked: 2
- 24. Conduct of clinical trials of medical products during the COVID-19 public health emergency: guidance for industry, investigators, and institutional review boards. Silver Spring, MD: Food and Drug Administration, August 30, 2021 (https:// www . fda . gov/ media/ 136238/ download/ ). Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the
- 3. ogy/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935-59.
Cited by
Items 801–900 of 1,003
Kumar, A. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.1058 · Cited by 7
Bharaj, I. S., Purewal, K., Munaim, J., Brar, A. S., Kacheria, A., Simister, A., Thirupathy, U., Gupta, P., Kahlon, J., Thwe, E. E., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13092192 · Cited by 7
“Both 52-week trials were randomized, double-blind, and placebo-controlled [74].”
The evolution of artificial intelligence technology in non-alcoholic fatty liver disease
He, J., Wu, Y., Lin, Z., He, R., Li, Z., & Li, Y. (2025) · Frontiers in Radiology · doi:10.3389/fradi.2025.1634165 · Cited by 5
Giannakogeorgou, A., KAHL, S., Granata, C., Heilmann, G., Mastrototaro, L., Dewidar, B., Bobrov, P., Esposito, I., Yavas, A., Trenkamp, S., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156391 · Cited by 5
Zambrano-Vásquez, O. R., Cortés-Camacho, F., Cabrera-Angeles, J. C., Hernández-Alba, A. L., García‐Arroyo, F. E., Castañeda‐Sánchez, J. I., Aréchaga-Ocampo, E., Aparicio‐Trejo, O. E., del Valle‐Mondragón, L., Martínez-Olivares, C. E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189010 · Cited by 4
Viebahn, G., Khurana, A., Freund, L., Chilin-Fuentes, D., Jepsen, K., Rosenthal, S. B., Chatterjee, S., Ellenrieder, V., Hsu, C. L., Schnabl, B., et al. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00164.2025 · Cited by 5
Idalsoaga, F. J., Díaz, L. A., Alghsoon, S. A., Lawendy, B., Sharma, N., Desalegn, H., Yuan, Y., Ha, M. K., Le, J., MacDonald, J. K., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.09.035 · Cited by 7
Self-citationXiao, Y., Zhang, X., Shao, B., Wu, Z., Li, X., Yi, D., Li, T., Yang, T., Zhu, J.-X., Huang, T., et al. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c07003 · Cited by 5
Quantitative Approaches to Accelerate MASH Drug Discovery and Development
Abouelhassan, Y., Tallapaka, S. B., Mehrani, R., Siler, S. Q., Li, Q., Wang, Z., & Trujillo, M. E. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70103 · Cited by 5
Putri, R. R. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1675713 · Cited by 8
Pathogenesis, diagnosis and management of chronic hepatitis B related liver fibrosis
Kösekli, M. A., & Aktaş, G. (2025) · Minerva Gastroenterology · doi:10.23736/s2724-5985.25.03862-8 · Cited by 5
Fu, W., Wang, J., Lu, N., Guo, Z., Ong, S., Gao, Y., Zhou, H., Chang, X., & Meng, M. (2025) · Cell Proliferation · doi:10.1111/cpr.70141 · Cited by 4
Novel Aurone Derivative Ameliorates MASH Lipid Metabolism via the AMPK-ACC-PPARα Axis
Bai, S., Zou, Y., Zhang, W., Yu, J., Qie, Z., Liu, Z., Yu, P., Xiang, C., & Teng, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211099 · Cited by 7
“Its hepatic benefits occur without THR-α -related cardiac or skeletal effects [17–20], though transient gastrointestinal side effects warrant further safety evaluation [18,19].”
Sugawara, T., Hitaka, K., Matsumoto, M., Nakamura, S., Kobayashi, R., Kandori, H., & Nio, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-24927-3 · Cited by 5
“Accordingly, resmetirom, an approved drug for MASH treatment, decreases LDL-C levels and improves liver fibrosis 41 .”
Wen, L., Wu, J., Zhao, Y., Sun, Z., Liang, C., Liu, X., Luo, J., & Li, X. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149042 · Cited by 4
Liver disease in people living with HIV infection: a changing landscape
Lee, F., & Bansal, M. B. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01149-6 · Cited by 8
“This oral once-daily THRB agonist is safe and well tolerated, and is the first drug to show fibrosis regression in non-cirrhotic MASH 137 .”
Self-citationGe, Y., Deng, S., Zhang, X., Liu, H., Chen, Y., Liu, Y., Liu, S., Fu, H., Yang, Y., & Wu, Z. (2025) · Food & Function · doi:10.1039/d4fo01605j · Cited by 4
Fu, R., Zhang, F., Fu, J., Li, Y., Zhu, X., Ding, Q., & Zhu, Y. Z. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.163 · Cited by 7
Abenavoli, L. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2607008 · Cited by 4
“Concurrently, investments in cost-effective, generic formulations of GLP-1 RAs and resme-tirom generics may enhance equitable access [15,16].”
Herdiana, Y. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s562536 · Cited by 4
MASLD as a complication of obesity must include liver risk stratification
Rinella, M. E., Sanyal, A. J., Loomba, R. S., Noureddin, M., Bansal, M. B., Newsome, P. N., & Ratziu, V. (2026) · Nature Medicine · doi:10.1038/s41591-025-04130-7 · Cited by 4
Self-citationStokar, J., & Dresner–Pollak, R. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70121 · Cited by 5
“With the recent introduction of effective therapeutics for MASLD [18–20], early identification and screening of subjects at risk is key.”
Bile acids as therapeutic agents
Vu, B., Kawamoto, R., Villalba‐Davila, P., Dong, X., & Karnsakul, W. W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1732854 · Cited by 6
Guo, X., Yin, X., Liu, Z., & Wang, J. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121217 · Cited by 4
Siranart, N., Thompson, C. C., & Jirapinyo, P. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000871 · Cited by 8
“[5] With the escalating obesity and type 2 diabetes pandemic, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained widespread popularity.”
Ali, N., Alotaibi, F. T., Babu, M. A., Singh, T., Alaseem, A. M., Tyagi, Y., & Bansal, N. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70190 · Cited by 6
“In 2024, the US FDA approved Resmetirom (Rezdiffra) for the treatment of NASH, which selectively agonizes the thyroid hormone receptor‐beta (THR‐β) and improves lipophagy and β‐oxidation of hepatic fatty acids to help reduce liver fat [109, 110].”
Ng, N. B. H., Sng, A. A., & Huang, J. G. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i1.111211 · Cited by 6
Musso, G., Pinach, S., Cassader, M., Mariano, F., & Gambino, R. (2026) · Med · doi:10.1016/j.medj.2025.100959 · Cited by 4
Kim, G., Jang, H., Kim, M. Y., Park, J. H., Park, J. G., Cho, E.-Y., Jeong, J. Y., Jeong, S., Han, S. K., 권희수, et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.01.007 · Cited by 15
Chen, H., Ye, Y., He, T., Li, B., & Wang, Q. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02105-3 · Cited by 6
“Pharmacological interventions, including vitamin E, pioglitazone and resmetirom, have shown modest efficacy in specific patients, but their long-term safety and effectiveness are debated [17, 18].”
Rosoff, D. B., Wagner, J., Perlstein, T., Reitz, J., Jung, J., Blaney, H. L., Gharib, A. M., Hsu, C., Heller, T., Koh, C., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.01.025 · Cited by 7
Brouwer, W. P., Vonghia, L., Thiele, M. S., Schattenberg, J. M., Anastasiou, F., Beckmann, S., Bugianesi, E., Castéra, L., Caussy, C., Cordie, A., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101798 · Cited by 12
“2 Resmetirom 158,159 has been approved by the FDA for MASH with significant or advanced fibrosis in the absence of cirrhosis and is in use in the US.”
Self-citationKhalifa, O., & Arredouani, A. (2026) · Pharmaceuticals · doi:10.3390/ph19030408 · Cited by 8
Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Abreu, E. S., Noureddin, M., Takahashi, H., Schattenberg, J. M., & Abdelmalek, M. F. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.004 · Cited by 4
Self-citationResmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
van Kleef, L. A., Michel, M. S., Alkhouri, N., Brouwer, W. P., & Schattenberg, J. M. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s559331 · Cited by 13
“15 In the MAESTRO NASH study patients with active hyperthyroidism, untreated hypothyroidism or doses of thyroxin exceeding 200 micrograms were excluded from the MAESTRO-NASH trial.”
InfluentialSelf-citationNjei, B. M., Al‐Ajlouni, Y. A., Tanih, D. N., Kanmounye, U. S., Boateng, S., Halwani, K. W., Nguefang, G., & Lim, J. K. (2026) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-026-00741-0 · Cited by 4
“The phase III MAESTRO-NASH trial evaluated resmetirom in patients with biopsy-confirmed MASH and stage F2– F3 fibrosis and demonstrated significant improvements in fibrosis and steatohepatitis resolution at 52 weeks compared with placebo [10].”
van Eekhout, K. M. A., Broekman, L. D., de Jong, V., Michel, M. S., Grobbee, R., Maya‐Miles, D., Romero‐Gómez, M., Muris, J. W. M., Mendive, J. M., Vali, Y., et al. (2026) · Liver International · doi:10.1111/liv.70603 · Cited by 8
Self-citationMetabolic Dysfunction-Associated Steatotic Liver Disease
Paik, J. M., Henry, L. L., AlNaamani, K. M., Nader, A., Stepanova, M., Lee, M., Yu, M., & Younossi, Z. M. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.001 · Cited by 4
Self-citationLindstad, T. M., Pourteymour, S., Lee-Ødegård, S., Drevon, C. A., & Norheim, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27072941 · Cited by 5
“…thyroid hormone receptor-β agonist, is the first agent to receive FDA approval for the treatment of MASH with moderate to advanced fibrosis [11,12], whereas other candidates like semaglutide (GLP-1 receptor agonist) and lanifibranor (pan-PPAR agonist) are in late-phase clinical trials…”
Schattenberg, J. M., Bédossa, P., Guy, C. D., Taub, R. A., Labriola, D., Zhang, H., Hennan, J. K., Camacho, R. C., Chng, E., Ren, Y., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.03.021 · Cited by 7
Self-citationAlamgir, M., Sohal, A., & Kowdley, K. V. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s560039 · Cited by 6
Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan
Seko, Y., & Yamaguchi, K. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02401-9 · Cited by 4
“Emerging therapies for MASH, including lifestyle interventions and drug treatment with resmetirom and semaglutide, are reshaping therapeutic strategies [10, 11].”
Baptista, C., Esteves, F., Fallowfield, J. A., Kendall, T. J., Nelson, L. J., & Kranendonk, M. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01202-y · Cited by 8
“In MASH, impaired thyroid hormone receptor-β (THRβ) function decreases mitochondrial activity, reduces fatty acid β-oxidation, and increases fibrosis 156 .”
MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues
Ha, S., Zhang, X., Lan-juan, L., & Yu, J. (2026) · 中国科学通报:英文版 · doi:10.1016/j.scib.2026.04.048 · Cited by 8
Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options
Ren, R., Liang, X., & Wei, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00486-5 · Cited by 6
Acierno, C., Caturano, A., Barletta, F., Rinaldi, L., Sasso, F. C., Adinolfi, L. E., & Nevola, R. (2026) · Nutrients · doi:10.3390/nu18111765 · Cited by 4
“As pharmacological options with stronger liver-centred evidence emerge—including GLP-1 receptor agonists and resmetirom [118]— the relevant question is no longer whether microbiome modulation should compete with drug therapy, but whether it can enhance response, improve metabolic context, or…”
MASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 7
Jayabaskaran, J., Nagarajan, S., Himan, H. R., Kok, J., Tan, E. E.-R., Chong, B., Kong, G., Chen, Y., Chew, H. S. J., Khan, M. S., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156716 · Cited by 5
Bjørndal, B., Tungland, S. L., Bohov, P., Sydnes, M. O., Dankel, S. N., Madsen, L., & Berge, R. K. (2024) · Liver Research · doi:10.1016/j.livres.2024.09.001 · Cited by 5
Prasad, K., Bhattacharya, D., Shams, S. G. E., Izarraras, K., Hart, T., Mayfield, B., Blaszczyk, M. B., Zhou, Z., Pajvani, U. B., Friedman, S. L., et al. (2024) · Cells · doi:10.3390/cells13191651 · Cited by 7
“Earlier this year, the thyroid hormone receptor β agonist Resmetirom was the first drug approved by the FDA to treat MASH, having shown improved key readouts of liver pathology in 25–30% of patients in a phase III clinical trial [53].”
BackgroundSuccessful Example of Implementing Screening of Liver Fibrosis in Specialist Diabetes Care
Tajudin, M., Hagström, H., & Rössner, S. M. (2024) · Gastro Hep Advances · doi:10.1016/j.gastha.2024.10.017 · Cited by 4
Theel, W. B., de Jong, V., Cabezas, M. C., Grobbee, D. E., Jukema, J. W., & Trompet, S. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14368 · Cited by 6
Karagiannakis, D. S., Stefanaki, K., Paschou, S. Α., Papatheodoridi, Μ., Tsiodras, S., & Παπάνας, Ν. (2024) · HORMONES · doi:10.1007/s42000-024-00625-z · Cited by 5
“In a phase III trial, resmetirom, a thyroid hormone receptor agonist highly selective for the b1 receptor, showed improved disease activity (resolution of steatohepatitis) and fibrosis in patients with F2 and F3 fibro - sis after 1 year of treatment [58].”
Dai, G., Lin, J., Jiang, Y., Liu, X., Chen, P., Zhang, Y., Song, Z., Zhuang, X., Cong, J., Li, Y., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1517226 · Cited by 5
Tie, F., Gao, Y., Ren, L., Wu, Y., Hu, N., Dong, Q. Z., & Wang, H. (2025) · Plant Foods for Human Nutrition · doi:10.1007/s11130-024-01262-y · Cited by 4
“Recent, Rezdiffra™ (resmetirom) is approved drug for first treatment for patients with NASH by U.S. Food and Drug Administration [5 ].”
de Jong, V., Theel, W. B., Cabezas, M. C., Grobbee, D. E., Jukema, J. W., & Trompet, S. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101337 · Cited by 6
Notch1 siRNA and AMD3100 Ameliorate Metabolic Dysfunction-Associated Steatotic Liver Disease
Zhu, C., Cheng, Y., Yang, L., Lyu, Y., Li, J., Zhao, P., Zhu, Y. J., Xin, X., & Yin, L. (2025) · Biomedicines · doi:10.3390/biomedicines13020486 · Cited by 5
“The good news is that the FDA approved the first drug for the treatment of MASH, Rezdiffra, in 2024, but the long-term efficacy of the drug is still being studied and evaluated [5].”
Vargas, C. C., Cáceres, F., Landeira, G., Perez, S., Marchi, L., Ruffillo, G., Tevez, S., Puga‐Tejada, M., & Fassio, E. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002943 · Cited by 4
“Recently, Food and Drug Administration in USA gave a conditional approval to resmetirom for the treatment of noncirrhotic MASH with fibrosis, based on the results of the phase 3, randomized, controlled vs placebo trial MAESTRO-NASH [46].”
Khalil, S. M., de Souza, M. H. G., de Oliveira, F. D., Sato, E. D. B. D. S., & Meine, G. C. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102579 · Cited by 6
Chen, J., Zhang, B., Cheng, Y., Jia, Y., & Zhou, B. (2025) · Diagnostics · doi:10.3390/diagnostics15091096 · Cited by 5
“Resmetirom is a liver-targeted, thyroid hormone receptor-β selective agonist that has shown promise in promoting the regression of MASH and ameliorating liver fibrosis [39].”
Predicting Fibrosis Stage in MASH: The Role of Total Metabolic Syndrome Score and MMP-1
Köylü, B., Sökmensüer, C., Karçaaltıncaba, M., & Keskın, O. (2025) · Medicina · doi:10.3390/medicina61061102 · Cited by 6
“Resmetirom has been recently approved by the U.S. Food and Drug Administration (FDA) as the first therapeutic agent targeting this high-risk subgroup [9,10].”
Tsai, C.-H., Hung, T., Wong, T.-S., Lin, C.-Y., Hsu, C.-L., Ko, P., Chou, Y.-C., Li, H.-F., Chien, S., & Hsu, C. (2025) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_158_25 · Cited by 5
“In March 2024, Resmetirom, a selective thyroid hormone receptor‑ β agonist, became the first FDA‑approved treatment for patients with MASH and fibrosis stages F2/ F3 [49].”
Li, N., Wu, S., Li, X., Yan, M., Ding, Y., Zhang, L., Brenner, D. A., Liu, X., & Kisseleva, T. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.06.012 · Cited by 6
Ren, Y., Chang, J. P. E., Tai, D., FILOZOF, C. M., Kleiner, D. E., & Sanyal, A. J. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.06.042 · Cited by 8
Self-citationSafety Choice Drivers of the Coming Treatment Options for Non‐Cirrhotic Metabolic Steatohepatitis
Mangia, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70271 · Cited by 4
“The first one, MAESTRO- NAFLD-1, did not require a baseline histological diagnosis [21], whereas the second, the MAESTRO NASH registration study required liver biopsy [20] confirmation and relied on histological outcomes for the first study phase [22].”
InfluentialSelf-citationExtrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
Shenoy, A., Ahmed, A., & Kim, D. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.73 · Cited by 10
Diagnosis and management of metabolic dysfunction associated steatotic liver disease
Musso, G., Lassen, A., Banda, L., Maher, J. J., & Gambino, R. (2025) · BMJ · doi:10.1136/bmj-2025-084950 · Cited by 6
“This was following the publication of a registrational phase 3 trial 47 where resmetirom treatment was associated with steatohepatitis resolutionin30%andwithfibrosisimprovementin26%ofpatients.”
Dicarboxylic acids counteract the metabolic effects of a Western diet by boosting energy expenditure
Castagneto‐Gissey, L., Bornstein, S. R., & Mingrone, G. (2024) · Journal of Clinical Investigation · doi:10.1172/jci181978 · Cited by 6
Fitzgerald, V. K., Lutsiv, T., McGinley, J. N., Neil, E. S., Playdon, M. C., & Thompson, H. J. (2024) · Nutrients · doi:10.3390/nu16183196 · Cited by 6
“Though it was only recently that the FDA approved the first drug for the treatment of MASH, lifestyle management remains a component of the first-line treatment of MASH, particularly high-quality diet and exercise [8–11].”
BackgroundNo Difference in Liver Damage Induced by Isocaloric Fructose or Glucose in Mice with a High-Fat Diet
Hsu, W., Lee, M.-H., Lii, C., & Peng, C. (2024) · Nutrients · doi:10.3390/nu16203571 · Cited by 4
“Dietary composition, including ceramides, might be a promising therapy in the subsequent study.”
BackgroundSharma, A., & Lee, H. (2024) · Antioxidants · doi:10.3390/antiox13111389 · Cited by 4
“Nonetheless, in 2024, the Food and Drug Administration approved resmetirom for the treatment of NASH in adults in conjunction with diet and exercise, and is currently being reviewed in the EU for the treatment of NASH [20,21].”
Patel, R. B., Barnwal, S. K., A, A. M. S. M., & Francis, D. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.10.001 · Cited by 4
Metabolic-dysfunction associated steatotic liver disease (MASLD)
De, A., Panigrahi, M. K., Duseja, A. K., & Singh, S. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26711-6.00031-7 · Cited by 5
Sirlin, C. B., & Reeder, S. B. (2024) · Radiology · doi:10.1148/radiol.241876 · Cited by 5
Gu, M. J., Ahn, Y., Lee, Y. R., Yoo, G., Kim, Y., Choi, I., Ha, S. K., & Kim, D. (2024) · Nutrients · doi:10.3390/nu16234165 · Cited by 8
Yang, Y., Zhang, Y., Wang, L., He, G., Yang, X., & Qing, J. (2025) · DNA and Cell Biology · doi:10.1089/dna.2024.0198 · Cited by 4
Ayesh, H., Beran, A., Suhail, S., Ayesh, S. K., & Niswender, K. D. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2024-0140 · Cited by 6
Heldens, A., Casteleyn, C. R., Onghena, L., Antwi, M. B., Neyt, S., Descamps, B., Vanhove, C., Verhelst, X., Raevens, S., Vlierberghe, H. V., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117826 · Cited by 8
Buchanan, R. M., Reinson, T., Bilson, J., Woodland, H., Nwoguh, C. A., Cooper, K., Harris, S., Malone, K., & Byrne, C. D. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-088043 · Cited by 5
“With respect to the latter, on 14 March 2024, Resme-tirom 23 was given conditional approval by the US Food and Drug Administration for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring (fibrosis) alongside diet and exercise.”
Ahmed, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061841 · Cited by 5
“The drug resmetirom shows promising results in the management of NASH and liver fibrosis [10].”
Garg, A., Vasandani, C., Li, X., Quittner, C., & Yokoo, T. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf173 · Cited by 5
Yoo, J. H., Jun, J. E., Jeong, I., Ahn, K. J., Chung, H. Y., Lee, M., & Hwang, Y. (2025) · Diabetes · doi:10.2337/db24-0370 · Cited by 4
Zambrano-Vásquez, O. R., Cortés-Camacho, F., Castañeda‐Sánchez, J. I., Aréchaga-Ocampo, E., Valle-Velázquez, E., Cabrera-Angeles, J. C., Sánchez-Gloria, J. L., Sánchez‐Muñoz, F., Arellano-Buendía, A. S., Sánchez‐Lozada, L. G., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123638 · Cited by 7
Mohanty, A., Austad, K., Bosch, N. A., Long, M. T., Nolen‐Doerr, E., Walkey, A. J., Drainoni, M., Rizo, I. M., & Fantasia, K. L. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.04.014 · Cited by 6
The Inherent Value of Treating Metabolic Dysfunction–Associated Steatohepatitis
Lazarus, J. V. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.17129 · Cited by 4
Lipid Droplet Dynamics in Alcoholic Steatohepatitis
Omar, D. Y., Willoughby, M. M., Mostafa, N., Otakhor, K. O., Bhatt, S., Zaidi, M. A. A., & Schott, M. B. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.07.010 · Cited by 5
“131 Resmetirom’s liver specificity prevents deleterious thyromimetic consequences on other thyroid hormone — responsive organs, including the cardio-vascular system, bone, and pituitary gland.”
Frías, J. P., Schmouder, R., Lawitz, E., Zhang, Y., Zhou, H., Badman, M. K., Ukomadu, C., Weiss, H., Zack, J., Yadav, B., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70475 · Cited by 6
“…are still no globally approved pharmaceutical treatments, with only one drug (resmetirom, a thyroid hormone receptor beta-selective agonist that demonstrated improvement in liver fibrosis in patients with MASH in a phase 3 trial) [18–20] recently approved for use in the US and Europe [21, 22].”
Treatment and Management of Gastrointestinal Disorders
Montgomery, G., Patel, A., & Pfeil, S. A. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.010 · Cited by 4
Sex-specific associations of steatotic liver disease with vascular health
Kwan, A. C., Wang, M., Trivedi, H. D., Ji, H., & Cheng, S. C. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.003 · Cited by 4
Does an Aspirin a Day Take the MASLD Away?
Lonardo, A., & Zheng, M.-H. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02885-y · Cited by 3
Queathem, E. D., Stagg, D. B., Nelson, A. B., Chaves, A., Crown, S. B., Fulghum, K., d’Avignon, D. A., Ryder, J. R., Bolan, P. J., Hayir, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.17.618895 · Cited by 4
Redefining End Points in MASH Cirrhosis
García–Tsao, G. (2025) · New England Journal of Medicine · doi:10.1056/nejme2505834 · Cited by 4
Therapy of liver fibrosis: From conventional approaches to nanomaterials delivery systems
Chen, L., Duan, Y., Jiang, T., Mao, C., Zhu, X., & Wan, M. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.04.019 · Cited by 3
Ye, J., Zhu, W., Cui, Y., Zhang, Q., Xiong, Y., Jin, L., Wang, A., Lin, M., Dong, H., Liang, G., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114570 · Cited by 3
7. Management of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112151 · Cited by 3
Carvajal‐Gonzalez, S., Tuthill, T. A., Wong, V. W., Ashworth, A. L., Kayali, Z., Fournier, C., & Amin, N. B. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100669 · Cited by 3
Godwin, K. M., Grigoryan, L., Thrift, A. P., Duong, H. T., Kanwal, F., Giardina, T. D., Kadiyala, H., Zimolzak, A. J., Patidar, K. R., & El‐Serag, H. B. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-12737-2 · Cited by 3
“At present, there is one FDA-approved pharmacologic agent for treating MASH (resmetirom) [15], and several incretins have shown highly promising results in phase 2 trials [16].”
Pugliese, N., Deo, D. D., Soleri, M., Colapietro, F., Vettor, R., & Aghemo, A. (2025) · Nutrients · doi:10.3390/nu17101644 · Cited by 6
Yang, L., Li, W., Chen, Y., Ya, R., Qian, S., Liu, L., Hao, Y., Zai, Q., Xiao, P., Hwang, S., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.007 · Cited by 5
“To date, several candidate drugs targeting DNL and hepatic lipid metabolism have shown promising results in treating MASLD in clinical trials including the ACC inhibitor Firsocostat, the fibroblast growth factor 21 (FGF21) receptor agonist Pegbel-fermin (BMS986036), and the THR-ß agonist Resmetirom (MGL3196) 14 .”
InfluentialAssessment and management of portal hypertension in patients with MASLD: advances and caveats
Rojo, D., Jiménez-Masip, A., Pagès, L., Bañares, J., Sabiote, C., Martínez-Gómez, M., Aceituno, L., Cusidó, M. S., Salcedo-Allende, M. T., Calixto, Z., et al. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2530605 · Cited by 4
“Resmetirom is a MASH-targeted therapy that has received accelerated approval by FDA for adults with non-cirrhotic MASH who have significant liver fibrosis (F ≥ 2) [77].”
Self-citation
Metadata
- Authors
- Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., Anstee, Q. M., Abdelmalek, M. F., Younossi, Z., Baum, S. J., Francque, S., Charlton, M. R., Newsome, P. N., Lanthier, N., Schiefke, I., Mangia, A., Pericàs, J. M., Patil, R., Sanyal, A. J., Noureddin, M., Bansal, M. B., Alkhouri, N., Castera, L., Rudraraju, M., & Ratziu, V.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne (Q.M.A.), and the National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham (P.N.N.) — all in the United Kingdom; Pinnacle Clinical Research, San Antonio (S.A.H., M.R.), South Texas Research Institute, Edinburg (R.P.), and Houston Methodist Hospital, Houston Research Institute, Houston (M.N.) — all in Texas; Liverpat and University of Paris (P.B.), INSERM, Unité Mixte de Recherche Scientifique (UMRS) 1139, Centre de Recherche sur l’Inflammation (L.C.), and Sorbonne Université, ICAN Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris (APHP), INSERM, UMRS 1138, Centre de Recherche des Cordeliers (V.R.), Paris, and Université Paris-Cité, Department of Hepatology, Beaujon Hospital, APHP, Clichy (L.C.) — ...
- Universitat Autònoma de Barcelona (ES)
- Houston Methodist (US)
- ORCID
- Harrison, Stephen A.
- Guy, Cynthia D.
- Schattenberg, Jörn M.
- Loomba, Rohit
- Taub, Rebecca
- Neff, Guy W.
- Rinella, Mary E.
- Anstee, Quentin M.
- Abdelmalek, Manal F.
- Younossi, Zobair
- Baum, Seth J.
- Francque, Sven
- Charlton, Michael R.
- Newsome, Philip N.
- Lanthier, Nicolas
- Mangia, Alessandra
- Pericàs, Juan M.
- Patil, Rashmee
- Sanyal, Arun J.
- Noureddin, Mazen
- Bansal, Meena B.
- Alkhouri, Naim
- Rudraraju, Madhavi
- Ratziu, Vlad
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-08
- Volume
- 390
- Issue
- 6
- Pages
- 497-509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4391592880
- Cited by
- 2,084
- References
- 26
- Citations by year
- 2026: 797 · 2025: 807 · 2024: 478
- FWCI
- 635.31
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Open Access CRIS of the University of Bern
- Funders
- Madrigal Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- resmetirom, nonalcoholic steatohepatitis, liver fibrosis, thyroid hormone receptor beta agonist, NASH resolution, fibrosis regression, NAFLD activity score, LDL cholesterol, triglycerides, cirrhosis prevention, drug safety and tolerability
- MeSH terms
- Adult, Biopsy, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Liver, Liver Cirrhosis, Pyridazines, Uracil, Treatment Outcome, Thyroid Hormone Receptors beta, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.